“I think a virtual nurse can have the same sort of presence that a bedside nurse does. I like to think of a virtual nurse as pulling up a virtual chair next to that patient and spending time to ask questions and engage with them,” Laura Gartner, DNP, MS, RN, NEA-BC, associate chief nursing informatics officer for inpatient shared services and north region at Jefferson Health in the Philadelphia, PA, area told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at...

“Chemotherapy exposure during the first trimester is contraindicated and increases the risk of spontaneous abortion, fetal death, and major congenital malformations. Second- and third-trimester exposure may affect some body systems still developing and can still result in fetal growth restriction, low birth weight, and preterm labor. Yet, I do want to stress that pregnancy can remain a possibility,” Kelsey Miller, MSN, RN, AGCNS-BC, OCN®, clinical nurse specialist in oncology and infusion...

Episode 310: Pharmacology 101: Androgen Receptor Inhibitors and Antiandrogens “The things that I think creep up are things that unfortunately are quite common, and that’s hot flashes. I’ve had patients say that those are just overwhelming, and they want to go off therapy because of it. So I think talking about pharmacologic management, as well as lifestyle management, of hot flashes, are equally as important,” Rowena “Moe” Schwartz, PharmD, BCOP, FHOPA, professor of pharmacy practice at...

“It was really the ability to be able to connect with many individuals from my profession. Reflecting on what initially drew me to ONS Congress, I can’t help but reminisce about my first time attending in 2002. I was going down memory lane the other day and found some pictures from my first time attending. As I reflected, I could not help but feel immensely grateful for the support and education I received as a novice nurse during that time from attending Congress,” Jessica MacIntyre, DNP,...

“One of the things that I know Dr. [Tom] Connor worked on very heavily in his career is the long-term impact on the health of nurses and other exposed healthcare workers. We definitely need more longitudinal studies, which are difficult to do. And it’s not something that you see every day where I talk to chemo nurses and said, ‘Hey, I’ve been in this 20 years. It hasn't bothered me at all.’ Well, until it does. Therefore, it’s so important when we’re training incoming nurses—how very...

“When we’re talking about the role of nurses in addressing these challenges, they play a critical role because of when they actually get to see patients. And so, if we can help with early identification and assessment, really finding out, using financial screening tools to identify any patients that might be at risk, early on, of financial toxicity, that can really allow for timely interventions,” Sarah Paul, LCSW, OSW-C, senior director of social work at CancerCare in New York, NY, told...

“At the beginning, like when you first meet someone before they’ve even started anything, kind of get a baseline of ‘What’s your ability to complete your daily activities? How is your coordination? How’s your speech now? How is your writing ability?’ up front before we start anything that could be toxic. And then prior to every treatment, I tend to look at their gait, watch them walk in or walk out of the office, to see if they’re changing at all,” Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP®,...

“A couple of things I think are really important when you look at this class of drug: It developed by a concerted effort in cancer drug development to look at new agents that would be effective based on the mechanism. And then once they found a drug in this class that was beneficial, they further modified it to try to get better efficacy and less toxicity,” Rowena “Moe” Schwartz, PharmD, BCOP, FHOPA, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of...

“The prescribing information is really a reliable data-driven and comprehensively reviewed tool. That’s not just for healthcare providers when writing a prescription, but also, for example, it is a tool that can be used to generate educational content for healthcare systems as they update formularies and create drug information,” Elizabeth Everhart, MSN, RN, ACNP, associate director for labeling at the U.S. Food and Drug Administration (FDA) in Silver Spring, MD, told Jaime Weimer, MSN, RN,...

“First, you want to refer patients to an eye care provider prior to initiating therapy, and I think communication at this point is really important. You need to tell the eye care provider why they’re being referred, what treatment they’re getting, the most common ocular toxicities, and also what needs to be done at every visit. They need to do a visual acuity; they need to do a slit-lamp eye exam. And these eye care providers need to know that ahead of time, so they’re doing everything at...

“We’ve seen over and over from an access standpoint how that makes a difference, then especially when you’re looking across racial disparities, ethnic disparities, geographic disparities, that having that person who can break down those barriers then is a great equalizer in that process,” Bonny Morris, PhD, MSPH, RN, senior director of navigation at the American Cancer Society, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation...

“Social work was involved because we could be radiation gung-ho, ready to go; chemo can be ready, but whoops, this patient doesn’t have a ride. It can be little things like that, you know, where we kind of forget. That’s why you need kind of a multidisciplinary approach. If it’s not your social worker, your navigator is going to know more and be like, ‘This patient needs a ride. I’m working on gas cards.’ Something like that can also halt a patient starting [treatment],” ONS member John...

“Trying to give them as much autonomy as possible is really important. I always like to ask, ‘Would you like to have a conversation? Do you think that you can handle a conversation about advance care planning?’ Or ‘What you would want someone to do for you if you're not able to speak for yourself?’ They may say no, you know, and we have to respect that too,” Mandi Zucker, LSW, CT, executive director of End of Life Choices New York in New York City, told Jaime Weimer, MSN, RN, AGCNS-BS,...

“I can't stress enough how often I get questions about, ‘Is this the paclitaxel doing this? Is this the docetaxel doing this?’ And coming up with strategies to kind of help get our patients through with supportive care is important. It's a really big opportunity for pharmacists and our nurses to really provide it and help our patients get through and show the knowledge that we have and to help them,” Dane Fritzsche, PharmD, BCOP, oncology informatics pharmacist at the Fred Hutchinson Cancer...

“We are there for whatever issue, whether it's skin management or helping just cheer them on and manage small things or big things, you know, to get them through these treatments. And then as a patient completes the treatment, we continue the nurse education and [managing] the late toxicities,” Michele “Michi” Gray, RN, radiation oncology care coordinator at the Cleveland Clinic in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a...

 “What you teach patients about that the side effects may be somewhat different, because it's more of a regional treatment with less systemic toxicities, so it's teaching patients about the drugs, the side effects, and the actual procedure itself,” Lisa Hartkopf-Smith, MS, RN, AOCN®, CHPN, advanced practice nurse at OhioHealth Center in Columbus and ProMedica Cancer Institute in Toledo, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a...

“The search for daunorubicin’s sister really led to this discovery of doxorubicin, which is an analog with much greater activity. The discovery of doxorubicin can be coined kind of as, ‘one of the best drugs born in Milan, Italy.’ And after that, a few analogs were developed and tested, and two that we currently use today, are idarubicin and epirubicin,” Puja Patel, PharmD, BCOP, clinical oncology pharmacist at the Delnor Hospital Northwestern Medicine Cancer Center in Geneva, IL, told Jaime...

  “So much of this is just knowing what is their diagnosis, what medications are they on, what could be the root cause of this—where is their disease to begin with? There's really a lot of differential diagnosis and workup that has to be thought about, you know, when you're dealing with shortness of breath and pulmonary toxicities,” Beth Sandy, MSN, CRNP, OCN®, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told...

“AYAs are underrepresented in clinical trials and unfortunately have one of the highest rates of being uninsured of any population. So, this is really concerning for a lot of reasons and really impacts our ability to make a difference for their treatment and outcomes,” Stacy Whiteside, APRN, MS, CPNP-AC/PC, CPON®, nurse practitioner and fertility patient navigator in the Department of Hematology, Oncology, and Blood and Marrow Transplant at Nationwide Children’s Hospital in Columbus, OH,...

“I can think of examples where I have two patients. They have the same diagnosis, but they have two different insurance companies, treatment plan’s the same. ‘Patient A’ isn't going to get the optimal treatment plan because their insurance company won't approve it. ‘Patient B’ is going to get the Cadillac version of this treatment plan, and what am I supposed to do about it,” Lucia D. Wocial, PhD, RN, FAAN, HEC-C, senior clinical ethicist in the John J. Lynch Center for Ethics at the MedStar...

“With the turnover rates where they’re at now, there’s no way we can keep thinking how we did in the past—like, we have to. There’s no doubt. We have to think differently,” Deborah Cline, DNP, RN, associate professor in the Department of Graduate Studies with Cizik School of Nursing at UTHealth Houston in Texas, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about oncology nurse retention.  You can earn free NCPD contact...

  “A sense of belonging is what tethers us to those who share in our spaces that work with us. Belonging is fueled by a social connection, which is one of our basic human needs. When you feel safe, supported, and valued, you bring your full, authentic self to work and you’re fully engaged to work collaboratively to deliver the best patient care and quite frankly, be the best teammate ever,” Kecia Boyd, DNP, RN, NEA-BC, AOCNS ®, BMTCN®, director of inclusion, diversity, and equity in the...

“I think educating patients of what can happen and those are the symptoms you're really looking for to decrease this from getting to the severe level is like the sensory stuff. It's kind of your starting point and it progresses from there,” Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP®, hematology and oncology nurse practitioner at Jefferson Health Asplundh Cancer Pavilion in Willow Grove, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a...

“Our top priorities really revolve around ensuring that everybody, regardless of their income, regardless of their gender, regardless of their race, regardless of where in the country they live, has access to the very best care for them and their family. And then ensuring that nurses have all of the education and training and support that they need to provide that care,” Jaimie Vickery, ONS’s director of government affairs and advocacy, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of...

“I think that there are certain agents that are so foundational in some diseases that they will remain. Whether they remain first-line, maybe not; maybe they’ll go to second line as we see things evolve with new agents. Some of these drugs have been very effective in the diseases in which they are used to treat patients. There’s a long term place in therapy for these, and I think that will still be using these,” Rowena Schwartz, PharmD, BCOP, FHOPA, known to many as “Moe,” professor of...